UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 969

Sortiert nach

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Annals of oncology, 2017-10, Vol.28 (10), p.2340-2366

2017

Link zum Volltext

Verfügbarkeit prüfen

SP016 Statistical issues on biomarker ascertainment and power to detect interactions

European journal of cancer (1990), 2013-11, Vol.49, p.S5-S5

Bogaerts, J

2013

Link zum Volltext

Verfügbarkeit prüfen

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

European journal of cancer (1990), 2009-01, Vol.45 (2), p.228-247

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

JNCI : Journal of the National Cancer Institute, 2009-02, Vol.101 (3), p.142-152

2009

Link zum Volltext

Verfügbarkeit prüfen

Time-Delay-Integration Architectures in CMOS Image Sensors

IEEE transactions on electron devices, 2009-11, Vol.56 (11), p.2524-2533

2009

Link zum Volltext
IEEE_Xplore

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of oncology, 2014-06, Vol.25 (6), p.1128-1136

2014

Link zum Volltext

Verfügbarkeit prüfen

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

Annals of oncology, 2018-12, Vol.29 (12), p.2313-2327

2018

Link zum Volltext

Verfügbarkeit prüfen

SP 116 Omics-based tests: What is the evidence and how to present it?

European journal of cancer (1990), 2011, Vol.47, p.S1-S1

Bogaerts, J

2011

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of lymph nodes with RECIST 1.1

European journal of cancer (1990), 2009-01, Vol.45 (2), p.261-267

2009

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of four phase III RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as first-line endocrine therapy for HR+ advanced breast cancer

Annals of oncology, 2018-11, Vol.29, p.ix17-ix17

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Breast cancer research and treatment, 2018, Vol.167 (1), p.123-131

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial

European journal of cancer (1990), 2015-02, Vol.51 (3), p.301-309

2015

Link zum Volltext

Verfügbarkeit prüfen

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Annals of oncology, 2018-11, Vol.29 (11), p.2175-2182

2018

Link zum Volltext

Verfügbarkeit prüfen

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

Annals of oncology, 2015-02, Vol.26 (2), p.300-306

2015

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-12, Vol.26 (12), p.2505-2506

2015

Link zum Volltext

Verfügbarkeit prüfen

Mammographic screening detects low-risk tumor biology breast cancers

Breast cancer research and treatment, 2014-02, Vol.144 (1), p.103-111

2014

Link zum Volltext

Verfügbarkeit prüfen

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

ESMO open, 2021-06, Vol.6 (3), p.100117-100117, Article 100117

2021

Link zum Volltext

Verfügbarkeit prüfen

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size

European journal of cancer (1990), 2012-06, Vol.48 (9), p.1386-1391

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

European journal of cancer (1990), 2008-11, Vol.44 (17), p.2542-2545

2008

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’

Annals of oncology, 2018-03, Vol.29 (3), p.774-775

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al

Annals of oncology, 2018-05, Vol.29 (5), p.1335-1338

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio

Annals of oncology, 2018-02, Vol.29 (2), p.521-522

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Breast cancer research and treatment, 2017-06, Vol.163 (3), p.507-515

2017

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio

Annals of oncology, 2017-08, Vol.28 (8), p.2031-2032

2017

Link zum Volltext

Verfügbarkeit prüfen

Perspectives from the RECIST committee on what constitutes a good tumor response metric

Annals of oncology, 2015-03, Vol.26, p.ii13

Bogaerts, J.

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 969

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(769)
Mit Volltextzugriff
(870)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(606)
Life Sciences & Biomedicine
(356)
Humans
(316)
Female
(197)
Physical Sciences
(163)
Biological And Medical Sciences
(160)
Technology
(151)
Male
(147)
Medical Sciences
(138)
Physics
(130)
Adult
(128)
Middle Aged
(96)
Engineering
(92)
Infectious Diseases
(81)
Oncology
(77)
Engineering, Electrical & Electronic
(73)
Aged
(65)
Optics
(63)
Microbiology
(61)
Exact Sciences And Technology
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

ESMO-Magnitude of Clinical Benefit Scale version 1.1

SP016 Statistical issues on biomarker ascertainment and power to detect interactions

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

Time-Delay-Integration Architectures in CMOS Image Sensors

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

SP 116 Omics-based tests: What is the evidence and how to present it?

Evaluation of lymph nodes with RECIST 1.1

Meta-analysis of four phase III RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as first-line endocrine therapy for HR+ advanced breast cancer

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Mammographic screening detects low-risk tumor biology breast cancers

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’

Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al

Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio

Perspectives from the RECIST committee on what constitutes a good tumor response metric

Suchergebnisse filtern